Preventing Serious Health Consequences of Type 2 Diabetes
|
|
- Elfrieda Fisher
- 5 years ago
- Views:
Transcription
1 Preventing Serious Health Consequences of Type 2 Diabetes The Evidence Hertzel C. Gerstein MD MSc FRCPC Professor and Population Health Institute Chair in Diabetes Research McMaster University and Hamilton Health Sciences Hamilton, Ontario, Canada
2 Disclosures for Hertzel C. Gerstein Relationships with Commerical Interests Grants/Research Support: Speakers Honoraria: Consulting Fees: Sanofi, Lilly, Astra Zeneca, Merck Sanofi, Lilly, Merck Novo Nordisk, AstraZeneca, Boehringer Ingelheim Sanofi, Lilly, AstraZeneca, Merck, Novo Nordisk, Abbott, Boehringer Ingelheim, Jannsen
3 Outline What are the serious health consequences of diabetes? What is their link to glucose? What does glucose lowering do? What do the glucose-lowering drugs do in addition to lowering glucose? Preventive effect of non-glycemic therapies
4 Serious Health Consequences of Diabetes Blindness Cataracts Kidney Failure Nerve Damage/Pain Foot pain, ulcers Leg/Foot Amputations PVD MI & Strokes Heart Failure NASH/Cirrhosis Cancers Cognitive Decline Depression Sleep Apnea Hip Fractures Imbalance & Frailty Joint Complaints Erectile Dysfunction Sexual Dysfunction Infertility Gut Problems
5 Diabetes & Death by Comorbidity 128,843 deaths (N=689,300 in 91 cohorts up to 2013; median F/U=12.8y) a sex-adjusted to age 60; mortality is per 1000 py Emerging HCG 2018 Risk Factors Collaboration. JAMA 2015; 52-60
6 Years Life Lost by Comorbidity 128,843 deaths (N=689,300 in 91 cohorts up to 2013; median F/U=12.8y) Years Lost by a 60y Old Man Woman Diabetes Diabetes + MI or Stroke ~60% of years lost are due to vascular causes Emerging Risk Factors Collaboration. JAMA 2015; 52-60
7 7 Diabetes & Risk of Heart Failure Hosp/Death 60 HF ref: adjusted HR % CI ; p< Diabetes (HF ref) Cumulative incidence (%) HF pef: adjusted HR % CI ; p< Diabetes (HF pef) No diabetes (HF ref) No diabetes (HF pef) Follow-up (years) MacDonald et al. Eur Heart J 2008;29:
8 Outline What are the serious health consequences of diabetes? What is their link to glucose? What does glucose lowering do? What do the glucose-lowering drugs do in addition to lowering glucose? Preventive effect of non-glycemic therapies
9 Type 2 DM: A1c & the Hazard of Death Swedish Registry from 98: NEJM 2015;373:1720 Cases (N=435,369) vs. controls (5/case = 2,117,483) without diabetes Adjusted for sex, time-updated age, birth country, education, diabetes duration Mean follow-up = 5 y < > 75 < 6.9% 7%-7.8% 7.9%-8.7% 8.8%-9.6% 9.7%+ < 6.9% 7%-7.8% 7.9%-8.7% 8.8%-9.6% 9.7%+ < 6.9% 7%-7.8% 7.9%-8.7% 8.8%-9.6% 9.7%+ < 6.9% 7%-7.8% 7.9%-8.7% 8.8%-9.6% 9.7%+ HR
10 Outline What are the serious health consequences of diabetes? What is their link to glucose? What does glucose lowering do? What do the glucose-lowering drugs do in addition to lowering glucose? Preventive effect of non-glycemic therapies
11 Type 2 DM: Glucose Lowering Trials Study Duration (yrs) N Glycemia Target Achieved A1c UKPDS FPG < 6 (110) 7.0% vs. 7.9% ACCORD A1C < 6.0% 6.4% vs. 7.5% ADVANCE A1C < 6.5% 6.5% vs. 7.3% VADT A1C < 6.0% 6.9% vs. 8.4% UKPDS - Lancet 1998: ; ACCORD - NEJM 2011: ADVANCE - NEJM 2008: ; VADT - NEJM 360;
12 G Lowering & Eye/Kidney/Nerve Disease T2 DM RCTs, Single Patient Meta-analysis: Lancet D&E 2017;5:431
13 G Lowering & Eye/Kidney/Nerve Disease T2 DM RCTs, Single Patient Meta-analysis: Lancet D&E 2017;5:431
14 G Lowering & Eye/Kidney/Nerve Disease T2 DM RCTs, Single Patient Meta-analysis: Lancet D&E 2017;5:431
15 Meta-Analysis of Glucose Lowering Trials: CVD ACCORD ADVANCE UKPDS 5y) VADT Turnbull et al. Diabetologia 2009;2288
16 Outline What are the serious health consequences of diabetes? What is their link to glucose? What does glucose lowering do? What do the glucose-lowering drugs do in addition to lowering glucose? Preventive effect of non-glycemic therapies
17
18 SAVOR-TIMI 53 n = 16,492 3-P MACE EXAMINE n = 5,380 3-P MACE TECOS n = 14,671 4-P MACE CARMELINA n = 8,300 3-P MACE, renal composite Cefalu et al. Diabetes Care 2018;41:14 CAROLINA n = 6,115 3-P MACE EMPA-REG OUTCOME n = 7,020 3-P MACE ELIXA n = 6,068 4-P MACE SUSTAIN-6 n = 3,297 3-P MACE CANVAS n = 4,330 3-P MACE CANVAS-R n = 5,813 Progression of albuminuria EXSCEL n = 14,000 3-P MACE VERTIS CV n = 3,900 3-P MACE Dapa-HF n = 4,500 CV death, HF hospitalization, HF urgent visit REWIND n = 9,622 3-P MACE CREDENCE n = 4,200 ESRD, doubling of creatinine, renal/cv death DECLARE-TIMI 58 n = 17,150 3-P MACE, CVD Dapa-CKD n = 4,000 50% sustained decline in egfr or reaching ESRD or CV death or renal death EMPEROR- Reduced n = 2,850 CV death or HF hospitalization DPP-4 inhibitors SGLT2 inhibitors LEADER n = 9,340 3-P MACE FREEDOM-CVO n = 4,000 4-P MACE HARMONY n = 9,400 3-P MACE EMPEROR- Preserved n = 4,126 CV death or HF hospitalization GLP-1 receptor agonists Insulin TZD Acarbose DEVOTE n = 7,637 3-P MACE TOSCA.IT n = 3,371 4-P MACE ACE n = 6,526 5-P MACE (3-P MACE plus hospitalization for HF or unstable angina)
19 Glucose Lowering Drug Categories Sulfonylureas Metformin Acarbose Meglitinides Insulin TZDs DPP4 inhibitors GLP-1 receptor agonists SGLT-2 inhibitors Other drugs Colesevalam Bromocriptine Pramlintide not approved in Brazil ADA. Diabetes Care 2018; 41(Supp 1): S1-S153
20 Glucose Lowering Drug Categories Sulfonylureas Metformin Acarbose Meglitinides Insulin TZDs DPP4 inhibitors GLP-1 receptor agonists SGLT-2 inhibitors Other drugs Colesevalam Bromocriptine Pramlintide ADA. Diabetes Care 2018; 41(Supp 1): S1-S153
21 Glucose Lowering Drug Categories Sulfonylureas Metformin Acarbose Meglitinides Insulin TZDs DPP4 inhibitors GLP-1 receptor agonists SGLT-2 inhibitors Other drugs Colesevalam Bromocriptine Pramlintide not approved in Brazil ADA. Diabetes Care 2018; 41(Supp 1): S1-S153
22 Glargine Insulin: IFG, IGT, T2DM ORIGIN: NEJM 2012;367: HR (95% CI) P Insulin Standard N = 12,537; 59% with CVD; Mean A1c=6.4%; Mean age=64 /100 py /100 py 1 st Glargine-mediated Coprimary 1.02 (0.94, normoglycemia 1.11) 0.63 vs. no insulin nd Coprimary 1.04 (0.97, 1.11) 0.27 Median F/U = 6.2 yrs; Control 1 st primary event rate = 2.9%/yr Microvascular 0.97 (0.90, 1.05) Death 0.98 (0.90, 1.08) MI 1.02 (0.88, 1.19) Stroke 1.03 (0.89, 1.21) CV Death 1.00 (0.89, 1.13) CHF Hospital 0.90 (0.77, 1.05) Revascularized 1.06 (0.96, 1.16) HR Favors Insulin Favors Standard HR
23 Effect of Glargine on Recurrent Heart Failure ORIGIN Circulation 2018;137:89
24 Effect of Glargine on Recurrent Heart Failure ORIGIN Circulation 2018;137:89
25 Insulin Glargine & Serious Health Outcomes ORIGIN NEJM 2012: HR (95% CI) P Insulin Standard /100 py /100 py Angina 0.95 (0.85, 1.05) Unstable 0.91 (0.76, 1.08) New angina 0.72 (0.56, 0.93) Worsening 1.02 (0.89, 1.16) Amputation 0.89 (0.60, 1.31) CV Hosp 1.00 (0.95, 1.07) Non-CV Hosp 0.99 (0.94, 1.05) Any Cancer 1.00 (0.88, 1.13) Cancer Death 0.94 (0.77, 1.15) Favors Insulin Favors Standard HR
26 Degludec U100 vs. Glargine U100 : Ambulatory T2DM DEVOTE NEJM 2017 Online N = 7,637; 84% on insulin; Mean A1c=8.4%; Mean age = 65; Previous CV or Renal Disease = 86% Masked Degludec U100 vs. Masked Glargine U100 titrated to FG 4-5 (72-90) Median F/U =2.0 yrs; Glargine event rate = 4.7%/yr
27 Glucose Lowering Drug Categories Sulfonylureas Metformin Acarbose Meglitinides Insulin TZDs DPP4 inhibitors GLP-1 receptor agonists SGLT-2 inhibitors Other drugs Colesevalam Bromocriptine Pramlintide not approved in Brazil ADA. Diabetes Care 2018; 41(Supp 1): S1-S153
28 Pioglitazone: No DM post Stroke/TIA IRIS study; NEJM 2016 N = 3876, no DM with stroke/tia in prior 6 mo & HOMA IR > 3 24% euglycemic (FPG<5.6 mm & HbA1c < 5.7%) Pioglitazone 45 mg/d or placebo Median F/U = 4.8 yrs; Placebo Event Rate ~ 2.5%/yr
29 Glucose Lowering Drug Categories Sulfonylureas Metformin Acarbose Meglitinides Insulin TZDs DPP4 inhibitors GLP-1 receptor agonists SGLT-2 inhibitors Other drugs Colesevalam Bromocriptine Pramlintide not approved in Brazil ADA. Diabetes Care 2018; 41(Supp 1): S1-S153
30 Glucose Lowering Drug Categories Sulfonylureas Metformin Acarbose Meglitinides Insulin TZDs DPP4 inhibitors GLP-1 receptor agonists SGLT-2 inhibitors Other drugs Colesevalam Bromocriptine Pramlintide not approved in Brazil ADA. Diabetes Care 2018; 41(Supp 1): S1-S153
31 GLP1RA CVOTs: Meta-Analysis Bethel et al. Lancet 2018; 6:105 3 Point MACE 3 Point MACE Mortality Mortality Bethel et al. Lancet Bethel D&E et al. 2017; Lancet Online D&E 2017; Online
32 GLP1RA CVOTs: Meta-Analysis Bethel et al. Lancet 2018; 6:105 CV Death CV Death MI MI Stroke Stroke Bethel HCG 2018 et al. Lancet Bethel D&E et al. 2017; Lancet Online D&E 2017; Online HR
33 GLP1RA CVOTs: Meta-Analysis Bethel et al. Lancet 2018; 6:105 Severe Hypo Severe Hypo Pancreatitis Pancreatitis Pancreas Cancer Pancreas Cancer Bethel et al. Lancet Bethel D&E et al. 2017; Lancet Online D&E 2017; Online HR
34 HARMONY Outcomes Trial Time to MACE Outcome Lancet 2018; Online Cumulative Incidence (%) People at risk Placebo 4,732 Albiglutide 4, Placebo (428 events) Albiglutide (338 events) HR: 0.78 (95% CI 0.68, 0.90) P= ,460 4,503 Time (months) N = 9463 with prior CVD; Median 1.6 y f/u Albiglutide mg/wk vs. placebo 3,074 3,148 Event rate per 100 person-years Placebo 5.87 Albiglutide ,030 1,064
35 GLP1RA Meta-analysis Renal/Eye Effects Avgerinos et al. Diabetes Obesity Metabolism 2018: Online
36 Ongoing GLP1RA Trials REWIND (Dulaglutide Wkly): MACE (NCT *) N ~ 9901; DM with prior CVD (31%) or risk factors Began Aug 2011, est. completion 2018 (F/U~5 y) Dulaglutide 1.5 mg/wk vs. placebo PIONEER 6 (Oral Semaglutide - Daily): MACE N ~ 3000; DM age 50+ with CVD or age 60+ with > 1 RF Began Feb 2016, ext. completion Oct 2018 (F/U~1.5 y) Daily oral Semaglutide vs. placebo *Clinicaltrials.gov
37 Glucose Lowering Drug Categories Sulfonylureas Metformin Acarbose Meglitinides Insulin TZDs DPP4 inhibitors GLP-1 receptor agonists SGLT-2 inhibitors Other drugs Colesevalam Bromocriptine Pramlintide not approved in Brazil ADA. Diabetes Care 2018; 41(Supp 1): S1-S153
38 Empagliflozin: T2DM & Prior CVD EMPA-REG Outcome; NEJM 2015; 373:2217 N = 7020 men & women with prior CVD Empagliflozin 10 mg/d, 25 mg/d or placebo Median F/U = 3.1 yrs; Placebo Event Rate = 4.4%/yr
39 EMPA-REG: Other Outcomes Mortality & HF - NEJM 2015;373:2217 CV Death HR 0.62 (95% CI 0.49, 0.77) p< Heart Failure Hospitalization HR 0.65 (95% CI 0.50, 0.85) p= All Cause Mortality HR 0.68 (95% CI 0.57, 0.82) p<0.0001
40 Canagliflozin: Ambulatory T2DM CANVAS NEJM 2017;377:644 N = 10,142; 66% with CVD; Mean A1c=8.2%; Mean age = 63 Canagliflozin 100 mg or 300 mg/d vs. placebo Median F/U =2.4 yrs; Placebo event rate = 3.2%/yr CV Death, Nonfatal MI Nonfatal Stroke
41 Canagliflozin: Ambulatory T2DM CANVAS NEJM 2017;377:644 Mortality Heart Failure Hospitalization
42 Canagliflozin: Ambulatory T2DM - Amputations CANVAS NEJM 2017;377:644 In other analyses, amputations were independent of other risk factors Could this be due to volume depletion
43 Outline What are the serious health consequences of diabetes? What is their link to glucose? What does glucose lowering do? What do the glucose-lowering drugs do in addition to lowering glucose? Preventive effect of non-glycemic therapies
44 RCT- Proven Non-glycemic Protective Rx Eyes Eye exams; BP control; Fibrates? Kidneys BP control; RAS blockers Foot CVD Liver Inspection; Foot care Smoking cessation; LDL lowering; BP control; Beta Blockers; RAS blockers; ASA post MI; ASA+Rivaroxaban Weight loss, Bariatric Surgery
45 Summary Diabetes independently increases many serious consequences Glucose lowering clearly reduces eye & kidney disease with controversial effects on other consequences Glucose lowering drugs have important non-glycemic effects: Glargine, degludec, nateglinide, sitagliptin, alogliptin, saxagliptin, lixisenatide & acarbose safe, neutral effect on CVD Empagliflozin, canagliflozin, liraglutide, semaglutide & albiglutide reduce CVD & renal disease; exenatide may reduce death Pioglitazone reduces CVD in non-dm at risk for stroke Several nonglycemic therapies that work in people without diabetes also have protective effects in diabetes
46 Many Proven Ways to Reduce Outcomes in T2 DM We knew exactly how to reduce outcomes when we had no good data but now, after ~ 15 years of good clinical outcomes trials, we know how to reduce serious health outcomes in people with diabetes
Update on Diabetes Cardiovascular Outcome Trials
Update on Diabetes Cardiovascular Outcome Trials Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine
More informationUpdate on Cardiovascular Outcome Trials in Diabetes Jay S. Skyler, MD, MACP
Update on Cardiovascular Outcome Trials in Diabetes Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research InsAtute University of Miami Miller School of Medicine
More informationCan We Reduce Heart Failure by Treating Diabetes? CVOT Data on SGLT2 Inhibitors and GLP-1Receptor Agonists
Can We Reduce Heart Failure by Treating Diabetes? CVOT Data on SGLT2 Inhibitors and GLP-1Receptor Agonists Robert R. Henry, MD Professor of Medicine University of California, San Diego Relevant Conflict
More informationSystematically Assessing the Promise of Type 2 Diabetes Remission
Systematically Assessing the Promise of Type 2 Diabetes Remission Is this the Next Frontier of Diabetes Care? Hertzel C. Gerstein MD MSc FRCPC McMaster University & Population Health Research Institute
More informationCardiovascular Outcomes With Newer Diabetes Drugs: Results From The EMPA-REG and LEADER Trials
Cardiovascular Outcomes With Newer Diabetes Drugs: Results From The EMPA-REG and LEADER Trials Rajiv Roy, MD Endocrinology Sharp Rees-Stealy Medical Group Background Between 1990 and 2010: Incidence of
More informationManagement of Type 2 Diabetes Cardiovascular Outcomes Trials Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas
Management of Type 2 Diabetes Cardiovascular Outcomes Trials 2018 Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas Speaker Disclosure Dr. Blevins has disclosed that he has received grant support
More informationThe Death of Sulfonylureas? A Review of New Diabetes Medications
The Death of Sulfonylureas? A Review of New Diabetes Medications Kelly Hoenig, Pharm.D., BCPS Cedar Rapids Family Medicine Residency 2/4/17 Objectives Review GLP-1 Agonists, DPP-IV Inhibitors and SGLT-2
More informationDiabete: terapia nei pazienti a rischio cardiovascolare
Diabete: terapia nei pazienti a rischio cardiovascolare Giorgio Sesti Università Magna Graecia di Catanzaro Cardiovascular mortality in relation to diabetes mellitus and a prior MI: A Danish Population
More informationDiabetes and Heart Failure: The Role of SGLT2 Inhibitors
22 nd Annual Heart Failure 2018 Symposium Diabetes and Heart Failure: The Role of SGLT2 Inhibitors Gregg C. Fonarow, MD, FACC, FAHA, FHFSA Elliot Corday Professor of Cardiovascular Medicine UCLA Division
More informationUpdates in Diabetes and Cardiovascular Disease Management: Are You Making the Link?
Updates in Diabetes and Cardiovascular Disease Management: Are You Making the Link? Denise Kolanczyk, PharmD, BCPS AQ Cardiology 1 Erika Hellenbart, PharmD, BCPS 2 Jennifer D Souza, PharmD, CDE, BC ADM
More informationNewer Therapies for Type 2 Diabetes
Newer Therapies for Type 2 Diabetes Sandra Indacochea Sobel, MD Clinical Assistant Professor of Medicine Clinical Chief of Endocrinology, UPMC Mercy Division of Endocrinology, Diabetes, and Metabolism
More informationLATE BREAKING STUDIES IN DM AND CAD. Will this change the guidelines?
LATE BREAKING STUDIES IN DM AND CAD Will this change the guidelines? Objectives 1. Discuss current guidelines for prevention of CHD in diabetes. 2. Discuss the FDA Guidance for Industry regarding evaluating
More informationThe Flozins Quest for Clarity?
The Flozins Quest for Clarity? Choosing Wisely with Academic Detailing 2018 ARE THEY THE REAL DEAL Disclosure statements The Academic Detailing Service is operated by Dalhousie Continuing Professional
More informationOral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy
Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 7, 2012 VanderbiltHeart.com Outline
More informationLa lezione dei trials di safety cardiovascolare. Edoardo Mannucci
La lezione dei trials di safety cardiovascolare Edoardo Mannucci Conflitti di interessi Negli ultimi due anni, E. Mannucci ha ricevuto compensi per relazioni e/o consulenze da: Abbott, AstraZeneca, Boehringer
More informationIn compliance with the accrediting board policies, the American Diabetes Association requires the following disclosure to the participants:
In compliance with the accrediting board policies, the American Diabetes Association requires the following disclosure to the participants: Entity Activity Financial Consideration Comments Novo Nordisk
More informationMedical therapy advances London/Manchester RCP February/June 2016
Medical therapy advances London/Manchester RCP February/June 2016 Advances in medical therapies for diabetes mellitus Duality of interest: The speaker or institutions with which he is associated has received
More informationHalting the Rise, Newest Non- Insulin Options for Lowering A1c
Halting the Rise, Newest Non- Insulin Options for Lowering A1c Alecia Rottinghaus, PharmD PGY-1 Pharmacy Resident Iowa City Veterans Affairs Health Care System January 29 th, 2019 Disclosures Alecia Rottinghaus
More informationCurrent principles of diabetes management
Current principles of diabetes management Prof. Martin Haluzík, MD, DSc. 3 Department of Medicine, General University Hospital and 1st Faculty of Medicine, Charles University in Prague, Czech Republic
More informationHalting the Rise, Newest Non- Insulin Options for Lowering A1c
Halting the Rise, Newest Non- Insulin Options for Lowering A1c Alecia Rottinghaus, PharmD PGY-1 Pharmacy Resident Iowa City Veterans Affairs Health Care System January 29 th, 2019 Disclosures Alecia Rottinghaus
More informationCV outcomes Studies and Implications for diabetes management. Seraj Abualnaja, MD, FRCPC Consultant Interventional cardiologist DSFH
CV outcomes Studies and Implications for diabetes management Seraj Abualnaja, MD, FRCPC Consultant Interventional cardiologist DSFH Case 49 y female with the following medical problems DM typ2 Hypertension
More informationUpdate on Cardiovascular Outcome Trials in Diabetes. Rury R. Holman, FMedSci NIHR Senior Investigator 11 th February 2013
Update on Cardiovascular Outcome Trials in Diabetes Rury R. Holman, FMedSci NIHR Senior Investigator 11 th February 2013 Residual Vascular Risk in People with Diabetes 2 Analyses based on 530,083 participants
More informationCANVAS Program Independent commentary
CANVAS Program Independent commentary Cliff Bailey Aston University, Birmingham, UK 2017 Disclosures and disclaimers Clifford J Bailey CJB has attended advisory boards, undertaken ad hoc consultancy, received
More informationWhat s New in Type 2 Diabetes? 2018 Diabetes Updates
What s New in Type 2 Diabetes? 2018 Diabetes Updates Gretchen Ray, PharmD, PhC, BCACP, CDE Associate Professor, UNM College of Pharmacy January 28, 2018 gray@salud.unm.edu OBJECTIVES Describe the most
More informationDu gusts is megl che one. Edoardo Mannucci
Du gusts is megl che one Edoardo Mannucci Conflitti di interessi Negli ultimi due anni, E. Mannucci ha ricevuto compensi per relazioni e/o consulenze da: Abbott, AstraZeneca, Boehringer Ingelheim, Eli
More informationDiabetes and New Meds for Cardiovascular Risk Reduction. F. Dwight Chrisman, MD, FACC. Disclosures: BI Boehringer Ingelheim speaker
Diabetes and New Meds for Cardiovascular Risk Reduction F. Dwight Chrisman, MD, FACC Disclosures: BI Boehringer Ingelheim speaker 1 Prevalence of DM DM state specific prevalence 2006 4%-6% 6-8% 8-10% 10-12%
More informationTerapia con agonisti GLP1 e outcome cardiovascolare. Edoardo Mannucci
Terapia con agonisti GLP e outcome cardiovascolare Edoardo Mannucci Conflitti di interessi Negli ultimi due anni, E. Mannucci ha ricevuto compensi per relazioni e/o consulenze da: Abbott, AstraZeneca,
More informationCase Studies in Type 2 Diabetes Mellitus: Focus on Cardiovascular Outcomes Trials
Case Studies in Type 2 Diabetes Mellitus: Focus on Cardiovascular Outcomes Trials Louis Kuritzky MD Clinical Assistant Professor Emeritus Department of Community Health and Family Medicine College of Medicine
More informationCardiologists and HbA1c: Novel Diabetes Drugs and Cardiovascular Disease Outcomes
Biomarkers 2018 Cardiologists and HbA1c: Novel Diabetes Drugs and Cardiovascular Disease Outcomes Gregg C. Fonarow, MD, FACC, FAHA, FHFSA Elliot Corday Professor of Cardiovascular Medicine UCLA Division
More informationCardiovascular Impact of Medications for Treating Type 2 Diabetes
Friday CME Breakfast Lecture Cardiovascular Impact of Medications for Treating Type 2 Diabetes Thomas Blevins, MD Endocrinologist, Private Practice Texas Diabetes and Endocrinology Austin, Texas Educational
More informationWhat s New in Type 2 Diabetes? 2018 Diabetes Updates
What s New in Type 2 Diabetes? 2018 Diabetes Updates Jessica Conklin, PharmD, PhC, BCACP, CDE, AAHIP Associate Professor, UNM College of Phar macy jeconklin@salud.unm.edu Luis Gonzales, PharmD, PhC UNM
More informationNEW DIABETES CARE MEDICATIONS
NEW DIABETES CARE MEDICATIONS James Bonucchi DO, ECNU, FACE Adult Medicine and Endocrinology Specialists Disclosures Speakers bureau Sanofi AZ BI Diabetes Diabetes cost ADA 2017 data Ever increasing disorder.
More informationOverview T2DM medications. Winnie Ho
Overview T2DM medications Winnie Ho Diabetes in Australia 1.7 million Australians with diabetes, of these 85% have T2DM 2-fold excess risk CV death in patients with diabetes Risk factor for progression
More informationDiabetes Management in CAD Patients. Stuart R. Chipkin, MD Research Professor School of Public Health and Health Sciences University of Massachusetts
Diabetes Management in CAD Patients Stuart R. Chipkin, MD Research Professor School of Public Health and Health Sciences University of Massachusetts Disclosure Stuart R. Chipkin, MD, FACE Nothing to disclose
More informationCanadian Journal of Diabetes
Can J Diabetes 42 (2018) S88 S103 Contents lists available at ScienceDirect Canadian Journal of Diabetes journal homepage: www.canadianjournalofdiabetes.com 2018 Clinical Practice Guidelines Pharmacologic
More informationStephen Clement M.D. CDE Medical Director, Endocrine Services Inova Fairfax Hospital
Stephen Clement M.D. CDE Medical Director, Endocrine Services Inova Fairfax Hospital Financial Disclosures Consulting Panel for GSK on Hepatitis Vaccines Case Study BH is a 67 y/o female with T2 DM for
More informationCardiovascular Outcome Trials of Diabetes Medications: Translating Results into Practice
Presenter Disclosure Information Cardiovascular Outcome Trials of Diabetes Medications: Translating Results into Practice Carol Hatch Wysham, MD Clinical Professor of Medicine University of Washington
More informationEvaluating the Cardiovascular Benefits of Antidiabetic Medications
Evaluating the Cardiovascular Benefits of Antidiabetic Medications Target Audience: Pharmacists ACPE#: 0202-0000-18-054-L01-P Activity Type: Application-based Disclosures Stuart T. Haines has no relevant
More informationNo Increased Cardiovascular Risk for Lixisenatide in ELIXA
ON ISSUES IN THE MANAGEMENT OF TYPE 2 DIABETES JUNE 2015 Coverage of data from ADA 2015, June 5 9 in Boston, Massachusetts No Increased Cardiovascular Risk for Lixisenatide in ELIXA First Cardiovascular
More informationClinical Relevance of Blood Pressure Lowering Effect of Modern Antidiabetic Drugs
Clinical Relevance of Blood Pressure Lowering Effect of Modern Antidiabetic Drugs Professor Guntram Schernthaner Medical University of Vienna, Austria guntram.schernthaner@meduniwien.ac.at Agenda Glucose
More informationGLP-1 RECEPTOR AGONIST SHOULD I TRY IT? VERONICA BRADY, PHD, BC-ADM, CDE PROJECT ECHO JUNE 21, 2018
GLP-1 RECEPTOR AGONIST SHOULD I TRY IT? VERONICA BRADY, PHD, BC-ADM, CDE PROJECT ECHO JUNE 21, 2018 SOMETHING TO CONSIDER IF YOU COULD PRESCRIBE A MEDICATION FOR YOUR PATIENT WITH DIABETES THAT: DECREASED
More informationCardiovascular Consequences of Diabetes Mellitus
Cardiovascular Consequences of Diabetes Mellitus William J. Elliott, M.D., Ph.D. 05 MAY 18 Disclosure Statement The speaker s research and educational activities have been supported in the past (but NOT
More informationNew Strategies for Cardiovascular Risk reduction in Diabetes
New Strategies for Cardiovascular Risk reduction in Diabetes Dr. Godwin LEUNG Tat Chi MB ChB(HK), MRCP (UK), FHKCP, FHKAM (Medicine) FRCP (Glasg), FACC Specialist in Cardiology % event as first CV event
More informationGlucose Control and Prevention of Cardiovascular Disease
Glucose Control and Prevention of Cardiovascular Disease Dr Peter A Senior BMedSci MBBS PhD FRCP(E) Associate Professor, Director Division of Endocrinology, University of Alberta Diabetes Update+, March
More informationESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES
ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES Pr. Michel KOMAJDA Institute of Cardiology - IHU ICAN Pitie Salpetriere Hospital - University Pierre and Marie Curie, Paris (France) DEFINITION A
More informationType 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions
Diabetes Mellitus: Complications and Co-Morbid Conditions ADA Guidelines for Glycemic Control: 2016 Retinopathy Between 2005-2008, 28.5% of patients with diabetes 40 years and older diagnosed with diabetic
More informationDisclosures. Objectives. Bryan Cardiology Conference DM2 & Cardiovascular Outcome Trials 8/28/2017
Bryan Cardiology Conference DM2 & Cardiovascular Outcome Trials Shannon Wakeley MD Complete Endocrinology 9/2/2017 Disclosures Speakers Bureau: Astra Zeneca, Sanofi, Abbvie, Boehringer-Ingelheim, Medtronic,
More informationVascular complications
Vascular complications December 8, 2018 Faculty Disclosure Faculty: Kim Connelly, MBBS, PhD, FRACP Associate Professor of Medicine, University of Toronto Cardiologist, St. Michael s Hospital Relationships
More informationCardiovascular Benefits of Two Classes of Antihyperglycemic Medications
Cardiovascular Benefits of Two Classes of Antihyperglycemic Medications Nathan Woolever, Pharm.D., Resident Pharmacist Pharmacy Grand Rounds November 6 th, 2018 Franciscan Healthcare La Crosse, WI 2017
More informationCan Treating Diabetes with SGLT2 inhibitors Prevent Heart Failure?
UCSD Hawaii 2017 Symposium Can Treating Diabetes with SGLT2 inhibitors Prevent Heart Failure? Gregg C. Fonarow, MD, FACC, FAHA Elliot Corday Professor of Cardiovascular Medicine UCLA Division of Cardiology
More informationDiabetes new challenges, new agents, new order
Diabetes new challenges, new agents, new order Ken Earle St Georges University Hospitals NHS Foundation Trust Overview Cardiovascular disease unmet needs Treating evident and residual risk Integrating
More informationKeep Calm and Focus on the Evidence for the Management of Diabetes. Diabetes Update 2018
Keep Calm and Focus on the Evidence for the Management of Diabetes Diabetes Update 2018 Nicole C.Pezzino, PharmD, BCACP, CDE Assistant Professor, Wilkes University Pharmacist, Weis Markets Nicole.pezzino@wilkes.edu
More informationType 2 diabetes & Cardiovascular disease. update. Barcelona, March 15th 2018
Type 2 diabetes & Cardiovascular disease update Barcelona, March 15th 2018 Francesc Xavier Cos Claramunt Sant Martí de Provençals. Head of Innovation and Health in Barcelona city Assoc.ProfUniversitatAutonomade
More informationEmergence of the New Classes of Compounds for Managing Heart Disease in Diabetes Mellitus
Emergence of the New Classes of Compounds for Managing Heart Disease in Diabetes Mellitus Mikhail Kosiborod, MD Professor of Medicine (Cardiology) Saint Luke s Mid America Heart Institute University of
More informationCardiologists and HbA1c: Novel Diabetes Drugs and the Cardiologist as Diabetician
Biomarkers 2019 Cardiologists and HbA1c: Novel Diabetes Drugs and the Cardiologist as Diabetician Gregg C. Fonarow, MD, FACC, FAHA, FHFSA Elliot Corday Professor of Cardiovascular Medicine UCLA Division
More informationGli endpoint micro-vascolari nei trial di outcome cardiovascolare
Gli endpoint micro-vascolari nei trial di outcome cardiovascolare Giorgio Sesti University Magna Graecia of Catanzaro ITALY Potenziali conflitti di interesse Il Prof Giorgio Sesti dichiara di aver ricevuto
More informationHeart Failure Management in T2 DM A Practical Approach. David Fitchett MD St Michael s Hospital Toronto
Heart Failure Management in T2 DM A Practical Approach David Fitchett MD St Michael s Hospital Toronto Faculty: Faculty Disclosure David Fitchett MD,, FRCP(C) Associate Professor of Medicine, University
More informationMultiple Small Feedings of the Mind: Diabetes. Sonja K Fredrickson, MD, BC-ADM March 7, 2014
Multiple Small Feedings of the Mind: Diabetes Sonja K Fredrickson, MD, BC-ADM March 7, 2014 Question 1: Setting A1c Goals Describe the evidence based approach to determining the target HgbA1c in different
More informationEndocrinologist Sweetgrass Endocrinology
Endocrinologist Sweetgrass Endocrinology Sanders, Cummings Ask Justice Department to Investigate Insulin Prices The Department of Justice and the FTC are asked to investigate whether Lilly, Novo Nordisk,
More informationIndividualizing Management of T2DM in the Hospital Setting to Reduce Macro and Microvascular Complications
Individualizing Management of T2DM in the Hospital Setting to Reduce Macro and Microvascular Complications This CME activity is provided by Integrity Continuing Education. This CEU/CNE activity is co-provided
More informationMANAGING DIABETES IN 2016 WHAT TO ADD, WHEN AND WHY?
MANAGING DIABETES IN 2016 WHAT TO ADD, WHEN AND WHY? Faculty: Maria Wolfs MD, MHSc, FRCPC Assistant Professor, University of Toronto Staff Endocrinologist, St. Michael's Hospital Relationships with commercial
More informationCurrent Updates & Challenges In Managing Diabetes in CVD
Current Updates & Challenges In Managing Diabetes in CVD Preventive Cardiovascular Conference 2016 Instituit Jantung Negara 12 th November 2016 Nor Azmi Kamaruddin Diabetes Clinic Department of Medicine
More information2018 Diabetes Update
2018 Diabetes Update Jennifer D. Smith, PharmD, BCACP, BC-ADM, CDE Susan Cornell, PharmD, CDE, FAPhA, FAADE Midwestern University Chicago College of Pharmacy Target Audience: Pharmacists ACPE#: 0202-0000-18-043-L01-P
More informationEffect of SGLT-2 Inhibitors on the Heart. Robert Zimmerman MD Vice Chairman Endocrinology Director Diabetes Center Cleveland Clinic
Effect of SGLT-2 Inhibitors on the Heart Robert Zimmerman MD Vice Chairman Endocrinology Director Diabetes Center Cleveland Clinic Disclosures Speaker - Johnson and Johnson - Merck Research - Merck - Novo
More informationNavigating the New Options for the Management of Type 2 Diabetes
Navigating the New Options for the Management of Type 2 Diabetes Clinical Associate Professor Mark Kennedy Department of General Practice, University of Melbourne Chair, Primary Care Diabetes Society of
More informationDiabetes Drugs and Cardiac Disease. Disclosures
Diabetes Drugs and Cardiac Disease Robert J. Rushakoff, MD Professor of Medicine University of California, San Francisco robert.rushakoff@ucsf.edu Disclosures None 1 Written Comments As I have said every
More informationTop HF Trials to Impact Your Practice
Top HF Trials to Impact Your Practice Biykem Bozkurt, MD, FACC The Mary and Gordon Cain Chair & Professor of Medicine Medical Care Line Executive, DeBakey VA Medical Center, Director, Winters Center for
More informationDiabetes Mellitus: Implications of New Clinical Trials and New Medications
Diabetes Mellitus: Implications of New Clinical Trials and New Medications Estimates of Diagnosed Diabetes in Adults, 2005 Alka M. Kanaya, MD Asst. Professor of Medicine UCSF, Primary Care CME October
More informationDisclosures. Type 2 Diabetes. The New Epidemic: How Did We Get Here and What's to Come? Summary:
Type 2. The New Epidemic: How Did We Get Here and What's to Come? Robert J. Rushakoff, MD Professor of Medicine University of California, San Francisco None Disclosures robert.rushakoff@ucsf.edu Type 2.
More informationType 2 Diabetes Management: Case 1: Reducing Hypoglycemic Risk Case 2: Reducing Cardiovascular Risk
Type 2 Diabetes Management M. Susan Burke, MD, FACP Clinical Associate Professor of Medicine Sidney Kimmel Medical College at Thomas Jefferson University Senior Advisor, Lankenau Medical Associates Lankenau
More informationActualités en diabétologie Quoi de neuf en 2016? S. Aouiche Service de diabétologie CHU Mustapha Alger.Pr BOUDIBA
Actualités en diabétologie Quoi de neuf en 2016? S. Aouiche Service de diabétologie CHU Mustapha Alger.Pr BOUDIBA Deux médicaments valent mieux qu un dans le traitement du patient diabétique Jochen.SEUFERT
More informationEducational Objectives
Educational Objectives Recognize the rationale for cardiovascular outcome trials (CVOTs) in T2DM and review data from recent CVOTs of anti hyperglycemic agents Examine alignment of managed care T2DM treatment
More information7/8/2016. Sol Jacobs MD, FACE Division of Endocrinology Emory University School of Medicine
Sol Jacobs MD, FACE Division of Endocrinology Emory University School of Medicine Participation in investigator initiated clinical research supported by: Merck Boehringer Ingelheim Novo Nordisk Astra Zeneca
More informationMaking Sense of New DM Therapies and Technologies
Making Sense of New DM Therapies and Technologies Sandra Indacochea Sobel, MD Clinical Assistant Professor of Medicine Clinical Chief of Endocrinology, UPMC Mercy Division of Endocrinology, Diabetes, and
More informationMANAGING DIABETES IN 2017 WHAT TO ADD, WHEN AND WHY? December 8, 2017 Maria Wolfs MD MHSc FRCPC
MANAGING DIABETES IN 2017 WHAT TO ADD, WHEN AND WHY? December 8, 2017 Maria Wolfs MD MHSc FRCPC Faculty Disclosure Faculty: Maria Wolfs MD, MHSc, FRCPC Assistant Professor, University of Toronto Endocrinologist,
More informationThe Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
More information01/09/2017. Outline. SGLT 2 inhibitor? Diabetes Patients: Complex and Heterogeneous. Association between diabetes and cardiovascular events
MICROVASCULAR COMPLICATIONS Incidence of outcome g 1 Cardioprotective Effects of SGLT2s Relevant for Which T2 Diabetes Patient? SGLT 2 inhibitor? 58 year old, waist circumference 5 cm, PMH: IHD On statin,
More informationDisclaimers 22/03/2018. Role of DPP-4 Inhibitors, GLP-1 Agonists, and SGLT-2 Inhibitors in the treatment of Diabetes Mellitus Type 2
Disclaimers Role of DPP-4 Inhibitors, GLP-1 Agonists, and SGLT-2 Inhibitors in the treatment of Diabetes Mellitus Type 2 I have not received money or gifts from medical device companies or from the pharmaceutical
More informationSyllabi/Slides for this program are a supplement to the live CME session and are not intended for other purposes.
1: - 11:15 AM Decreasing Cardiovascular Risk with Antihyperglycemic Agents in Patients with T2DM SPEAKER Christopher P. Cannon, MD Bejamin M. Scirica, MD, MPH Disclosures This session is supported by an
More informationDiabetes Treatment Update
Diabetes Treatment Update Timothy C. Evans, MD PhD FACP University of Washington Department of Medicine Disclosure: Dr. Evans has no significant financial interest in any of the products or manufacturers
More informationGLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS FOR TYPE 2 DIABETES: A COMPREHENSIVE
ENDOCRINE PRACTICE Rapid Electronic Article in Press Rapid Electronic Articles in Press are preprinted manuscripts that have been reviewed and accepted for publication, but have yet to be edited, typeset
More informationThe Role Of SGLT-2 Inhibitors In Clinical Practice. Anne Peters, MD Professor, USC Keck School of Medicine Director, USC Clinical Diabetes Programs
The Role Of SGLT-2 Inhibitors In Clinical Practice Anne Peters, MD Professor, USC Keck School of Medicine Director, USC Clinical Diabetes Programs Disclosure of Potential Conflicts of Interest Consultantship
More informationVery Practical Tips for Managing Type 2 Diabetes
Very Practical Tips for Managing Type 2 Diabetes Jean-François Yale, MD, FRCPC McGill University Health Centre, Montreal, Canada Jean-francois.yale@mcgill.ca www.dryale.ca OBJECTIVES DISCLOSURES The participant
More informationHelp the Heart. An Update on GLP-1 Agonists and SGLT2 Inhibitors. Tara Hawley, PharmD PGY1 Pharmacy Resident Mayo Clinic Health System Eau Claire
Help the Heart An Update on GLP-1 Agonists and SGLT2 Inhibitors Tara Hawley, PharmD PGY1 Pharmacy Resident Mayo Clinic Health System Eau Claire Mayo Clinic Grand Rounds May 16, 2017 2017 MFMER slide-1
More informationPHARMACOLOGIC APPROACH TO ACHIEVE GLYCEMIC GOAL
Dr Aurora Alcantara Endocrinology PHARMACOLOGIC APPROACH TO ACHIEVE GLYCEMIC GOAL SPED Convention and Diabetes Postgraduate Course May26-29 Wyndham Grand Rio Mar, PR DISCLOSURES Speaker for the following
More informationDiabetic Management of the Cardiac Patient
Diabetic Management of the Cardiac Patient Dr Peter A Senior BMedSci MBBS PhD FRCP(E) Associate Professor, Director Division of Endocrinology, University of Alberta Disclosures Grants/Research Support:
More informationLEADER and EMPA-REG. John Buse, MD, PhD. University of North Carolina School of Medicine Chapel Hill, NC, USA. Duality of Interest Declaration
1 LEADER and EMPA-REG John Buse, MD, PhD University of Nth Carolina School of Medicine Chapel Hill, NC, USA Duality of Interest Declaration I rept the following potential duality/dualities of interest
More informationTHE EVOLUTION OF CLINICAL TRIALS IN T2DM: FROM TARGETING A1C TO TARGETING CARDIOVASCULAR OUTCOMES
Learning Objectives 1) Evaluate the interrelationship between diabetes, glycemic control, and cardiovascular disease. 2) Examine the evolution of type 2 diabetes (T2DM) drug development and factors leading
More informationSGLT2 Inhibitors Improve CardioRenal Outcomes in DM2-Get Rid of the Sugar
SGLT2 Inhibitors Improve CardioRenal Outcomes in DM2-Get Rid of the Sugar David Balis, MD University of Texas Southwestern Medical Center Internal Medicine Grand Rounds 10/6/17 This is to acknowledge that
More informationManaging Perioperative Diabetes What s new? Kathryn A. Myers MD FRCPC Chair Chief Division of GIM Professor of Medicine Western University
Managing Perioperative Diabetes What s new? Kathryn A. Myers MD FRCPC Chair Chief Division of GIM Professor of Medicine Western University Objectives: By the end of this session, you will be able to: Identify
More informationPharmacology Updates. Quang T Nguyen, FACP, FACE, FTOS 11/18/17
Pharmacology Updates Quang T Nguyen, FACP, FACE, FTOS 11/18/17 14 Classes of Drugs Available for the Treatment of Type 2 DM in the USA ### Class A1c Reduction Hypoglycemia Weight Change Dosing (times/day)
More informationReview of FDA Guidance on Cardiovascular Outcomes for Diabetes Medication Trials and Application to Clinical Management
Katherine S. O Neal Pharm.D., MBA, BCACP, CDE, BC-ADM, AE-C Associate Professor The University of Oklahoma Health Sciences Center College of Pharmacy Department of Internal Medicine Oklahoma City, OK Member,
More informationHow to Use the ADA Type 2 Diabetes Treatment Algorithm. Eric L. Johnson, MD Jay Shubrook, Jr., DO, FACOFP
How to Use the ADA Type 2 Diabetes Treatment Algorithm Eric L. Johnson, MD Jay Shubrook, Jr., DO, FACOFP 8 ACOFP 55th Annual Convention & Scientific Seminars ACOFP FULL DISCLOSURE FOR CME ACTIVITIES Please
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC Choosing the Right Agent for your Patient with diabetes: Individualizing type 2 diabetes management in light of the expanding therapies
More informationPROTECTING YOUR SWEET HEART
PROTECTING YOUR SWEET HEART Cardiovascular risk reducdon in diabetes too many choices and so much confusion! Dr. Arden Barry, BSc, BSc(Pharm), PharmD, ACPR Clinical Pharmacy and Research Specialist, Chilliwack
More informationNewer Diabetes Treatments Drug Class Update with New Drug Evaluation: Semaglutide and Ertugliflozin
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationDrug Class Update with New Drug Evaluation: Non-insulin Diabetes Treatments (SGLT-2 Inhibitors and GLP-1 Receptor Agonists)
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationOLD AND NEW DRUGS FOR CONTROLING DIABETES THERAPEUTIC CLASSES AND MECHANISM OF ACTION
OLD AND NEW DRUGS FOR CONTROLING DIABETES THERAPEUTIC CLASSES AND MECHANISM OF ACTION Biljana Parapid, MD, PhD, FESC Belgrade University School of Medicine, Belgrade (Serbia) @biljana_parapid COI International
More informationGlucose Lowering Medications and CV Risk Reduction: A New Era Jane EB Reusch MD ADA President for Medicine and Science
Glucose Lowering Medications and CV Risk Reduction: A New Era Jane EB Reusch MD ADA President for Medicine and Science Professor of Medicine, Division of Endocrinology, Metabolism and Diabetes and Associate
More informationOral Agents in Type 2 DM
Oral Agents in Type 2 DM CME Away India & Sri Lanka March 23 - April 7, 2018 Richard A. Bebb MD, ABIM, FRCPC Consultant Endocrinologist Medical Subspecialty Institute Cleveland Clinic Abu Dhabi Copyright
More information